Gerresheimer AG (DE:GXI)
XETRA:GXI
Top Page
Gerresheimer
(XETRA:GXI)
Select Model
Select Model
Rating:49Neutral
Price Target:
€25.00
▼(-11.10% Downside)
Action:ReiteratedDate:11/06/25
Gerresheimer's overall stock score of 49 reflects a cautious outlook, driven primarily by mixed financial performance with steady revenue growth offset by negative free cash flow and rising debt levels. Bearish technical indicators further weigh on the score, with the stock trading well below key moving averages. A high P/E ratio suggests overvaluation, though a strong dividend yield offers some appeal.
Positive Factors
Revenue Growth
Gerresheimer's consistent revenue growth indicates strong market demand and business expansion, supporting long-term sustainability.
Negative Factors
Profitability Margins
Decreased net profit margin due to cost pressures may impact long-term profitability if not managed effectively.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Gerresheimer's consistent revenue growth indicates strong market demand and business expansion, supporting long-term sustainability.
Read all positive factors
Gerresheimer (GXI) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€641.06M
Dividend Yield0.15%
Average Volume (3M)538.00K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth11.83%
EPS Growth-79.57%
CountryDE
Employees13,632
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.06
Shares Outstanding34,540,000
10 Day Avg. Volume723,177
30 Day Avg. Volume537,996
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)1.71
Price to Sales (P/S)1.27
P/FCF Ratio-19.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€26.61Price Target Upside-5.36% Downside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)2.38
Revenue Forecast (FY)€2.36B
Gerresheimer Business Overview & Revenue Model
Company Description
Gerresheimer AG is a leading global partner for the pharmaceutical and healthcare industries, specializing in the development and production of high-quality glass and plastic packaging solutions. The company operates in various sectors, including ...
How the Company Makes Money
Gerresheimer generates revenue primarily through the sale of its packaging products and solutions to pharmaceutical and healthcare companies. Key revenue streams include the production of primary packaging for injectable medications, which is a ra...
Gerresheimer Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 | Nov 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.25B | 2.04B | 1.99B | 1.82B | 1.50B | 1.42B |
| Gross Profit | 605.15M | 607.76M | 597.31M | 546.81M | 442.23M | 437.61M |
| EBITDA | 394.95M | 405.97M | 403.89M | 340.20M | 293.09M | 301.41M |
| Net Income | 23.35M | 109.72M | 116.13M | 96.12M | 83.79M | 88.56M |
Balance Sheet | ||||||
| Total Assets | 4.69B | 3.81B | 3.43B | 3.35B | 2.88B | 2.62B |
| Cash, Cash Equivalents and Short-Term Investments | 145.87M | 213.06M | 122.34M | 124.83M | 133.78M | 100.72M |
| Total Debt | 2.31B | 1.28B | 1.04B | 1.22B | 1.13B | 1.05B |
| Total Liabilities | 3.26B | 2.27B | 1.96B | 2.08B | 1.88B | 1.72B |
| Stockholders Equity | 1.40B | 1.51B | 1.45B | 1.24B | 981.32M | 883.83M |
Cash Flow | ||||||
| Free Cash Flow | -86.72M | -129.51M | -33.70M | -16.13M | 8.45M | 49.12M |
| Operating Cash Flow | 253.62M | 240.33M | 294.34M | 221.94M | 212.08M | 222.19M |
| Investing Cash Flow | -671.26M | -345.59M | -307.43M | -256.18M | -197.04M | -157.03M |
| Financing Cash Flow | 463.09M | 168.27M | 40.35M | 44.24M | 8.03M | -52.15M |
Gerresheimer Technical Analysis
Negative
28.12
Price Trends
20.99
Negative
23.53
Negative
32.05
Negative
Market Momentum
-0.08
Negative
48.33
Neutral
45.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:GXI, the sentiment is Negative. The current price of 28.12 is above the 20-day moving average (MA) of 19.28, above the 50-day MA of 20.99, and below the 200-day MA of 32.05, indicating a neutral trend. The MACD of -0.08 indicates Negative momentum. The RSI at 48.33 is Neutral, neither overbought nor oversold. The STOCH value of 45.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:GXI.
Gerresheimer Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €1.67B | 15.56 | 7.38% | 1.97% | -5.27% | -13.70% | |
65 Neutral | €2.22B | 17.81 | 6.77% | 1.50% | 7.82% | -19.80% | |
62 Neutral | €1.63B | 25.83 | 5.63% | 4.66% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | €13.12B | 110.19 | 5.77% | 0.39% | 5.82% | 59.90% | |
49 Neutral | €641.06M | -30.69 | 1.59% | 0.15% | 11.83% | -79.57% | |
46 Neutral | €13.12B | 110.19 | 5.01% | 0.30% | 5.82% | 59.90% |
* Healthcare Sector Average
DE:GXI
Gerresheimer
18.56
-45.74
-71.13%
DE:AFX
Carl Zeiss Meditec
24.84
-25.82
-50.97%
DE:JEN
Jenoptik
29.12
12.63
76.55%
DE:PFV
Pfeiffer Vacuum Technology
165.00
17.03
11.51%
DE:SRT
Sartorius
167.20
7.89
4.95%
DE:SRT3
Sartorius
212.40
13.84
6.97%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.